Baker Bros. Buys $24.3M of Kodiak Sciences at $98.51, Adding to 20.4M-Share Stake
KOD has more than doubled off its 52-week low of $15.833.
Summary
Baker Bros. bought 247,090 Kodiak Sciences shares for $24.3 million at $98.51 on November 4-5, lifting its stake to 20.4 million shares. The open-market purchase extends the firm's post-DAYBREAK accumulation.
Key Events · Ownership and Investor Activity · KOD
-
Baker Bros. Adds 247,090 Shares
Baker Bros. Advisors and affiliates bought 247,090 shares for $24,340,836 at $98.51 across four transactions on 2026-11-04 and 2026-11-05.
-
Stake Reaches 20.4 Million Shares
Post-transaction holdings total 20,424,859 shares, held indirectly through 667, L.P. and Baker Brothers Life Sciences, L.P.
-
Follows September Accumulation
Comes after the group's $58.6 million purchase reported 2026-09-30, the day Kodiak disclosed positive DAYBREAK Phase 3 results.
-
Going-Concern Risk Persists
The Q2 2026 10-Q reiterated that cash of $125.9 million may not cover the next 12 months; a new $350 million at-the-market program was registered 2026-10-20.
Analysis · KOD · Life Sciences
Baker Bros. Advisors and affiliates, including director and 10% owner Julian Baker, bought 247,090 shares for $24.3 million at $98.51 on November 4-5. This is real open-market cash, not an option exercise, and it extends a pattern of accumulation: the same group bought $58.6 million in late September after the DAYBREAK Phase 3 win. The purchase is modest relative to Kodiak's roughly $6.2 billion market value, but it shows the largest holder still adding near the 52-week high of $104. The main risk remains the going-concern warning from the Q2 10-Q, which said cash may not cover the next 12 months; the new $350 million at-the-market program registered October 20 is the likely funding backstop.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $99.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $15.83 to $104.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.